Determining the metastable zone and avoiding polymorphism - Pfizer, Inc.

Mark B. Mitchell, Pfizer, Inc.

      

Lasentec® FBRM® was used to examine the crystallization of a two-form monotropic system in which Form B had issues symptomatic of a large fines count. By using FBRM® to determine the metastable curve, chemists gained an effective window for seeding, ultimately improving the system's bulk properties.

Downloaden:

Read the full Determining the metastable zone and avoiding polymorphism Application Note (M-2-225) (pdf - 116 KB)

Request more information about Determining the metastable zone and avoiding polymorphism

Products and Solutions

• FBRM® and PVM® Particle System Characterization Solutions for Production
• FBRM® and PVM® Particle System Characterization Solutions for the Lab

Applications

• Polymorph and Pseudo-polymorph Transition in-process monitoring of habit change
• Micromixing and Mesomixing Effects on Nucleation, Agglomeration, and De-agglomeration Kinetics in a Dye Precipitation - Sepracor, Inc.
• Resolving Batch-Processing Problems in Drug Manufacturing - GlaxoSmithKline
• Online Monitoring of Crystallization of a Polymorphic Compound Using FBRM®, PVM®, and Raman
• Solubility Curve and Metastable Zone Width Measurement Using Lasentec® FBRM® and PVM® - University College Dublin
• Detecting Optimal Seed Volume and Anti-solvent Addition Rate - DuPont Pharmaceuticals Company
• Optimizing a Crystallization Process in a Manufacturing Environment - Pfizer Global Manufacturing

• Home
• Application Descriptions
• Determining the metastable zone and avoiding polymorphism - Pfizer, Inc.